Last --
Change Today 0.00 / 0.00%
Volume 0.0
4519 On Other Exchanges
Symbol
Exchange
4519 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, and Perjeta; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, respiratory diseases, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; and co-development agreement with Taisho Pharmaceutical Co., Ltd., as well as co-marketing agreement with Taisho Toyama Pharmaceutical Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

6,872 Employees
Last Reported Date: 03/27/14
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical Co. Ltd. Provides Dividend Guidance for the Year End of Fiscal 2014

Chugai Pharmaceutical Co. Ltd. provided dividend guidance for the year end of fiscal 2014. For the end of fiscal year 2014, the company expects to pay dividend of JPY 23 per share compared to JPY 23 per share paid in a year ago.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2014; Provides Consolidated Earnings Guidance for the First Nine Months and Full Year of Fiscal 2014

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported revenues were ¥333,426 million against ¥306,533 million a year ago. Operating profit was ¥59,134 million against ¥58,160 million a year ago. Profit before taxes was ¥59,420 million against ¥56,722 million a year ago. Net income was ¥40,575 million or ¥72.79 diluted per share against ¥38,984 million or ¥70.01 diluted per share a year ago. Net income attributable to Chugai shareholders was ¥39,730 million against ¥38,164 million a year ago. An increase in revenues for the third quarter of 8.8% year on year, an increase in the operating profit for the third quarter of 1.5% year on year, and an increase in the net income for the third quarter of 4.1% year on year. These results include non-core items, such as amortization of intangible assets of ¥0.9 billion, restructuring costs of ¥0.1 billion, and other items, which are excluded from the core results managed by Chugai. Increase in the revenues for the third quarter due to the strong growth in sales and increase in royalties and other operating income. As a result, an increase in the core operating profit of 1.9% year on year and an increase in the core net income of 4.3% year on year. Cash flows from operating activities were ¥27.5 billion against ¥43.0 billion a year ago. Purchase of property, plant and equipment was ¥12,083 million against ¥9,391 million a year ago. Purchase of intangible assets was ¥2,446 million against ¥1,740 million a year ago. The company provided consolidated earnings guidance for the first nine months of fiscal 2014 and full year ending December 2014. For the nine-month period, the company expects revenues were ¥333,426 million, core operating profit was ¥60,073 million and core earnings per share were ¥73.85. For the year, the company expects revenues were ¥451,000 million, core operating profit was ¥71,000 million and core earnings per share were ¥82.62.

Chugai Pharmaceutical Co. Ltd., Q3 2014 Earnings Call, Oct 24, 2014

Chugai Pharmaceutical Co. Ltd., Q3 2014 Earnings Call, Oct 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥3,050.00 JPY 0.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.85 USD +0.15
Bristol-Myers Squibb Co $59.58 USD +0.43
Eli Lilly & Co $70.39 USD +0.23
Merck KGaA €78.24 EUR -1.47
Teva Pharmaceutical Industries Ltd $57.18 USD +0.09
View Industry Companies
 

Industry Analysis

4519

Industry Average

Valuation 4519 Industry Range
Price/Earnings 29.0x
Price/Sales 3.4x
Price/Book 2.6x
Price/Cash Flow 29.7x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.